Novacyt (ALNOV) Q2 2025 TU earnings summary

Executive summary

• Unaudited Group statutory revenue for H1 2025 expected at approximately £9.8 million, compared to £10.0 million in H1 2024, restated to exclude IT-IS International revenue.

• Underlying Group revenue grew by about 2% (4% at constant currency), excluding the Taiwan service laboratory divestment.

• Clinical segment delivered encouraging growth, with sales reaching £6.9 million.

• NIPT technologies sales increased over 10% year-over-year to £2.4 million.

• APAC region achieved approximately 9% year-over-year growth, driven by strong demand for Reproductive Health products.

Financial highlights

• Cash position at 30 June 2025 was £23.8 million, down from £30.5 million at 31 December 2024.

• The Group remains debt free and expects its cash runway to be sufficient to reach EBITDA profitability.

Outlook and guidance

• Management remains focused on executing growth strategies to achieve EBITDA profitability following restructuring and consolidation.